Primary disease(s) |
Source |
Review
characteristics |
Participants |
Intervention |
Outcomes |
Behcet’s disease
|
Akiyama et al.2020[22]
|
20 clinical studies
were analyzed in the current study
AMSTAR Score 8/11
|
47 patients with Behcet’s disease treated with tocilizumab
|
Tocilizumab
8 mg/kg/4 weeks
|
Tocilizumab was shown as a promising treatment choice for refractory
ocular-, neuro-, and vasculo-Behcet’s disease, as well as secondary
amyloidosis, but this drug was not recommended for mucocutaneous and
articular involvement.
|
Polymyalgia Rheumatica
|
Akiyama et al.2020[23]
|
9 clinical studies were included in the current study.
AMSTAR Score 8/11
|
59 patients with isolated PMR treated with tocilizumab
|
Tocilizumab
8 mg/kg/4 weeks
|
Tocilizumab is effective in cases of isolated PMR, particularly in
combination with glucocorticoids. In addition to its
glucocorticoid-sparing effect, it achieves glucocorticoid free remission
and reduces relapse rates. Tocilizumab monotherapy is not
recommended.
|
Ankylosing Spondylitis |
Chen et al.
2016[24]
|
14 RCTs were
included in the network meta-analysis
AMSTAR Score
10/11
|
2672 active AS patients |
infliximab 3 mg/kg at weeks 0, 2, 6
and every 6 weeks for 12 weeks. secukinumab 2 10 mg/kg given 3 weeks
apart for 28 weeks. tocilizumab 8 mg/kg/4 weeks for 12 weeks. |
Our
analysis shows that except for the finding that infliximab 5 mg was
superior to tocilizumab, no differences between biologic therapies in
the treatment of AS. Infliximab 5 mg/kg may be a better biologic therapy
regimen for AS, but this interpretation should be accepted very
cautiously. Secukinumab also appears promising, though additional data
is warranted. |